ATARA BIOTHERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $394.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $394.00K, a 85.93% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $749.00K, a 82.20% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.23M, a 80.92% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.80M, a 55.79% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $9.75M, a 63.88% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $27.00M, a 40.51% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $45.39M, a 15.70% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $53.84M, a 0.05% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 4 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $394.00K 10-Q · filed 2026-08-12 | $1.14M derived: sum of 2 quarters · filed 2026-08-12 | |||
| 2026-03-31 | $749.00K 10-Q · filed 2026-08-12 | ||||
| 2025-12-31 | $9.75M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $1.23M 10-Q · filed 2025-11-12 | $4.03M derived: sum of 2 quarters · filed 2026-08-12 | $8.23M derived: sum of 3 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $2.80M 10-Q · filed 2026-08-12 | $7.01M derived: sum of 2 quarters · filed 2026-08-12 | |||
| 2025-03-31 | $4.21M 10-Q · filed 2026-08-12 | ||||
| 2024-12-31 | $27.00M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $6.42M 10-Q · filed 2025-11-12 | $12.76M derived: sum of 2 quarters · filed 2025-11-12 | $21.16M derived: sum of 3 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $6.34M 10-Q · filed 2025-11-12 | $14.73M derived: sum of 2 quarters · filed 2025-11-12 | |||
| 2024-03-31 | $8.40M 10-Q · filed 2025-11-12 | ||||
| 2023-12-31 | $45.39M 10-K · filed 2025-03-07 | ||||
| 2023-09-30 | $11.14M 10-Q · filed 2024-11-12 | $23.70M derived: sum of 2 quarters · filed 2024-11-12 | $35.46M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $12.55M 10-Q · filed 2024-11-12 | $24.32M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $11.76M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $53.84M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $14.02M 10-Q · filed 2023-11-01 | $28.14M derived: sum of 2 quarters · filed 2023-11-01 | $42.48M derived: sum of 3 quarters · filed 2023-11-01 | ||
| 2022-06-30 | $14.12M 10-Q · filed 2023-11-01 | $28.45M derived: sum of 2 quarters · filed 2023-11-01 | |||
| 2022-03-31 | $14.34M 10-Q · filed 2023-11-01 | ||||
| 2021-12-31 | $53.87M 10-K · filed 2023-02-08 | ||||
| 2021-09-30 | $13.76M 10-Q · filed 2022-11-08 | $27.57M derived: sum of 2 quarters · filed 2022-11-08 | $39.84M derived: sum of 3 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $13.81M 10-Q · filed 2022-11-08 | $26.07M derived: sum of 2 quarters · filed 2022-11-08 | |||
| 2021-03-31 | $12.27M 10-Q · filed 2022-11-08 | ||||
| 2020-12-31 | $51.35M 10-K · filed 2023-02-08 | ||||
| 2020-09-30 | $13.26M 10-Q · filed 2021-11-04 | $27.20M derived: sum of 2 quarters · filed 2021-11-04 | $39.85M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $13.95M 10-Q · filed 2021-11-04 | $26.59M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $12.64M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $51.70M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $12.15M 10-Q · filed 2020-11-09 | $27.35M derived: sum of 2 quarters · filed 2020-11-09 | $39.62M derived: sum of 3 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $15.20M 10-Q · filed 2020-11-09 | $27.47M derived: sum of 2 quarters · filed 2020-11-09 | |||
| 2019-03-31 | $12.27M 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | $33.82M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $9.25M 10-Q · filed 2019-11-07 | $17.25M derived: sum of 2 quarters · filed 2019-11-07 | $24.26M derived: sum of 3 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $8.00M 10-Q · filed 2019-11-07 | $15.01M derived: sum of 2 quarters · filed 2019-11-07 | |||
| 2018-03-31 | $7.01M 10-Q · filed 2019-11-07 | ||||
| 2017-12-31 | $23.10M 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $16.78M 10-K · filed 2019-02-26 | ||||
| 2015-12-31 | $10.25M 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | $10.10M 10-K · filed 2017-03-09 | ||||
| 2013-12-31 | $1.71M 10-K · filed 2016-03-04 | ||||
| 2012-12-31 | $292.00K 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |